Symbol not found
Stock Predictions, Articles, and News
- From the Web
From Analyst Ratings
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Enlivex Therapeutics (ENLV – Research Report), with a price target of $22.00. The company’s shares closed last Monday at $5.60, close to its 52-week low of $3.59. According to TipRanks.com, Selvaraju is a top 100 analyst with an average return
From Seeking Alpha
Moxian (NASDAQ:MOXC) +52% on merger with Btab.VBI Vaccines (NASDAQ:VBIV) +38%.ZAGG (NASDAQ:ZAGG) +21% as InvisibleShield screen protection with exclusive partner Kastus anti-microbial technology confirmed to kill human coronavirus.ReneSola (NYSE:SOL) +20% on Q2 results.Veoneer (NYSE:VNE) +20%.Clovis Oncology (NASDAQ:CLVS) +15% as FDA OKs FoundationOne CDx as a companion Dx for Clovis Oncology's rucaparib.Flux Power Holdings (NASDAQ:FLUX) +15%.Abercrombie & Fitch (NYSE:ANF) +11% on Q2 results.Box (NYSE:BOX) +10% on Q2 results.Abbott Laboratories (NYSE:ABT) +10% on FDA approval win of $5, 15-minute COVID test.GrowGeneration (NASDAQ:GRWG) +9%.Enlivex Therapeutics (NASDAQ:ENLV) +8%.NetApp (NASDAQ:NTAP) +8% on Q1 results.Urban One (NASDAQ:UONE) +8%.electroCore (NASDAQ:ECOR) +7% on publication in brain stimulation highlighting non-invasive vagal nerve stimulation’s potential role in treatment of post-traumatic stress disorder.Pluristem Therapeutics (NASDAQ:PSTI) +7%.on Q2 results.AgEagle Aerial Systems (NYSEMKT:UAVS) +7%.Collier Creek Holdings (NYSE:CCH) +6%.Arbutus Biopharma (NASDAQ:ABUS) +5% on agreement with Assembly Biosciences.Can-Fite BioPharma (NYSEMKT:CANF) +5% on 1H reults.
From Seeking Alpha
The first patient has been dosed in an investigator-initiated study evaluating Enlivex Therapeutics' (NASDAQ:ENLV) Allocetra, on top of standard-of-care treatment, in severely ill COVID-19 patients with respiratory failures.The co-primary endpoints are safety and the change in PaO2/FiO2 ratio number (measure of respiratory failure).The study is being conducted independently from the company's Phase 2b study of Allocetra in sepsis-related organ failure that will launch next quarter.Allocetra is an immune-balancing cell therapy designed to avert cytokine storms (excessive and potentially life-threatening immune responses) and restore immune balance.Shares up 6% premarket on light volume.